Abiopharma

EyePoint Pharmaceuticals Inc (EYPT) Announces Clinical Trial Update EyePoint Pharmaceuticals Inc (EYPT) provided an update on its clinical development programs. Clinical Development Highlights:

• Drug Program: passion, experience
• Diseases/Conditions: her career, sustained intraocular drug delivery
• Collaboration: EYPT
  • targeting wet age-related macular degeneration. The proven Durasert drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. EYEPOINT PHARMACEUTICALS SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995
  • planned for wet AMD and non-proliferative diabetic retinopathy in 2022